Importantly, in July 2018, Allergan and Molecular Partners announced that Abicipar pegol, a DARPin engineered to target vascular endothelial growth factor (VEGF), had reached the primary end point in two Phase III trials for the treatment of neovascular age-related macular degeneration (AMD). Here, VEGFA is linked to age-related macular degeneration.